Ambryon Biosciences

AAV1 Serotype

Natural AAV serotype with strong skeletal and cardiac muscle tropism. One of the earliest discovered and most clinically relevant serotypes for muscle-directed gene therapy.

TropismSkeletal muscle, cardiac muscle, CNS (moderate)

Characteristics

High skeletal muscle transduction efficiency. Strong cardiac muscle tropism. Moderate CNS penetration following direct injection. Heparan sulfate proteoglycan (HSPG) binding. Moderate pre-existing immunity in human populations (~40% seropositive). Uses sialic acid as cellular receptor.

Applications

Limb-girdle muscular dystrophy (clinical trials). Alpha-1 antitrypsin deficiency (Glybera - first approved AAV gene therapy in EU, now withdrawn). Lipoprotein lipase deficiency. Duchenne muscular dystrophy. Heart failure gene therapy.

Sequence1 bp

Sign in to view the full sequence.

Sign in

References

  1. 1.Xiao et al. (1999). Gene therapy vectors based on adeno-associated virus type 1. J Virol — Xiao 1999 AAV1

Identifiers & revision